Radiotherapy and complementary individualized treatment for cervical cancer

5^th World Congress on Cancer Therapy

September 28-30, 2015 Atlanta, USA

P Moreno-Acosta, A Romero, O Gamboa, M Cotes, J Acosta, G Aguilera and N Magne

National University of Colombia, Colombia

Posters-Accepted Abstracts: J Cancer Sci Ther

Abstract :

Cervical cancer is one of the most prevalent malignancy and of higher mortality in the world, and is considered a marker of underdevelopment. Conventional radiotherapy is one of the treatments used for this type of cancer. 30 to 40% of patients with similar prognosis factors not respond equally to a comparable standard treatment. The poor response to radiotherapy leads to the development of innovative and effective therapies for cervical cancer locally advanced, metastatic and refractory. A comparative analysis of cervical cancer in the context of other cancers may reveal that it is relatively smaller number of targeted molecular agents that have been tested. Accordingly, a number of biological agents are currently in clinical development for the purpose of, inhibiting angiogenesis, molecularly address EGFR and IGF-1R, modulation of cell cycle, of histone deacetylases, COX-2, mTOR and tumor microenvironment (hypoxia and glycolysis). Inhibitors of IGF-1R enthusiastically arrived at the clinic on the basis of preclinical targeting activity of IGF-1R, and the recognition that low IGF bioactivity system protects against cancer. Within work that we have been developing in cervical cancer with relationship to treatment, we reported that gene expression of IGF1R is a strong predictive marker for lack of response to radiotherapy, patients with expression of IGF1R have 28.6 times higher risk of failure treatment; the expression of IGF-IR�² detected by immunohistochemistry is a prognostic marker that affects overall survival and disease-free survival; the detection and study before treatment of the expression of CAIX, GLUT 1 and HKII, considered as biological factors pre-existing, contributes to infer the metabolic and hypoxic state, as also at the rational use of new modalities in radiotherapy and gene therapy in the regulation of hypoxia.

Biography :

Email: pmoreno@cancer.gov.co